| Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? V Ronco, M Dilecce, E Lanati, PL Canonico, C Jommi Journal of Pharmaceutical Policy and Practice 14 (1), 30, 2021 | 60 | 2021 |
| X-linked hypophosphatemic rickets: an Italian experts’ opinion survey F Emma, M Cappa, F Antoniazzi, ML Bianchi, I Chiodini, C Eller Vainicher, ... Italian journal of pediatrics 45, 1-7, 2019 | 50 | 2019 |
| Primary Biliary Cholangitis: advances in management and treatment of the disease P Invernizzi, A Floreani, M Carbone, M Marzioni, A Craxi, L Muratori, ... Digestive and Liver Disease 49 (8), 841-846, 2017 | 31 | 2017 |
| HCV: Estimation of the Number of Diagnosed Patients Eligible to New Anti-HCV Therapies in Italy I Gardini, M Bartoli, M Conforti, FS Mennini, A Marcellusi, EP Lanati Value in Health 19 (7), A510, 2016 | 21 | 2016 |
| Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study P Verdecchia, A D’Onofrio, V Russo, F Fedele, F Adamo, G Benedetti, ... Journal of Cardiovascular Medicine 20 (2), 66-73, 2019 | 18 | 2019 |
| Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco D Lidonnici, V Ronco, M Isernia, E Lanati, C Jommi, PL Canonico, ... Global & Regional Health Technology Assessment 2018, 2284240318792449, 2018 | 14 | 2018 |
| The burden of atopic dermatitis in adults in Italy. P Sciattella, G Pellacani, PD Pigatto, A Patrizi, K Peris, ... Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa …, 2019 | 13 | 2019 |
| From off-label to repurposed drug in non-oncological rare diseases: definition and state of the art in selected EU countries P Minghetti, EP Lanati, J Godfrey, O Solà-Morales, O Wong, S Selletti Medicine Access@ Point of Care 1, maapoc. 0000016, 2017 | 12 | 2017 |
| Valutazione economica di un programma di screening anti-HCV in Italia A Cicchetti, M Ruggeri, S Coretti, A Piscaglia, FR Ponziani, E Lanati, ... PharmacoEconomics Italian Research Articles 2 (13), 81-99, 2011 | 5 | 2011 |
| Le tempistiche autorizzative di AIFA: un confronto tra le due commissioni consultive e tecnico-scientifiche succedutesi nel periodo 2015-2020 P Raimondo, G Casilli, M Isernia, D Lidonnici, R Ravasio, V Ronco, ... Global & Regional Health Technology Assessment 7, 109, 2020 | 2 | 2020 |
| PMU42-ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL EP Lanati, A Isernia, VL Orlando Value in Health 21, S315, 2018 | 2 | 2018 |
| New drugs approval in Italy: updated analysis of the applied negotiation conditions 2015-2017 D Lidonnici, EP Lanati, S Niedecker, M Isernia Value in Health 21, S92, 2018 | 2 | 2018 |
| Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto FS Mennini, P Pisanti, S Terzoni, EP Lanati, A Marcellusi, A Marcelli, ... Global & Regional Health Technology Assessment 2018, 2284240318759426, 2018 | 2 | 2018 |
| EPIDEMIOLOGIA DEL MIELOMA MULTIPLO E CARATTERISTICHE CLINICHE DEI PAZIENTI Epidemiology of multiple myeloma and clinical characterization of patients L Scotti, V Montefusco, EP Lanati, VL Orlando, A Iorio, V Verdini Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione 10 (2), 23-30, 2018 | 2 | 2018 |
| Rwd Study for Epidemiology and Characteristics of Patients with Multiple Myeloma in Italy G Corrao, V Montefusco, F De Solda, P Finsinger, E Lanati, VL Orlando, ... Blood 128 (22), 5693, 2016 | 2 | 2016 |
| Italian timings in new drugs approval: an up-to-date analysis EP Lanati, D Lidonnici, V Ronco Value in Health 19 (7), A448, 2016 | 2 | 2016 |
| Adapting The Adpkd Outcomes Model to Predict Cost Consequence In Italian Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd) Treated With Jinarc (Tolvaptan) FS Mennini, A Marcellusi, S Russo, A Iorio, EP Lanati, P Robinson Value in Health 18 (7), A755, 2015 | 2 | 2015 |
| The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020 P Raimondo, G Casilli, M Isernia, D Lidonnici, R Ravasio, V Ronco, ... Global and Regional Health Technology Assessment 7 (1), 109-114, 2020 | 1 | 2020 |
| Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era J Jackson, T Mittendorf, CA Hill, S Bénard, EP Lanati ISPOR Europe 2019, 2019 | 1 | 2019 |
| PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY G Casilli, D Lidonnici, M Morichi, M Isernia, E Lanati Value in Health 22, S716, 2019 | 1 | 2019 |
